Finance

Umbilical cord blood stem cell bank-focused company completes round of financing

Published in Blood Weekly, August 18th, 2005

StemCyte, Inc., an umbilical cord blood stem cell transplantation and therapeutic products company, announced it has recently completed a significant round of financing from new investors within both the United States and abroad. StemCyte sold approximately $13.7 million of new securities.

StemCyte, Inc., and its subsidiary in Taiwan, maintain one of the largest and most ethnically diverse collections of donated cord blood stem cells in the world and have now provided transplant and cancer centers with umbilical cord blood units for over 200 stem cell transplantation procedures worldwide. Cord blood stem cells have proven to be an effective substitute for traditional...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry